PDP
PDP
Skip to content Skip to navigation menu
Your browser is not supported by this site.
Please update to the latest version, or use a different browser for the best experience.
Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio

Product details:

Format: Book - hardbound
Brand: American Bar Association
ISBN: 9781627227315
Service #: 41694430
Pages: 832
Shelf Space: 2 in.
Publication frequency: As needed
Update method: No updating

Can we help?

Contact Us 
Call 1-888-728-7677

Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio

104470731

Availability:

In stock
(details)
104470731
104470731
One time purchase
$275.00
Purchase the current version only, no updates will be sent.


Published by the American Bar Association (ABA), Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio is an in-depth resource for learning about and planning for ANDA litigations and all the different avenues that pharmaceutical litigants could follow.

All pharmaceutical companies, whether they are an innovator or a generic, must navigate the same complex legal and regulatory framework to bring a product to market and fend off competition. From the perspective of an innovator company, patents are vital to protect new drug products both to recoup the initial investment and for future investments. For the innovator and patent owner, the patentee must be aware of the risk to those intellectual property rights and be prepared for any patent challenge. Both entities can use Pre-ANDA Litigation as a resource to help formulate a strategy before patent litigation begins.

Patent litigations and strategies are complex and will require the patent professional to be able to explain complex technical and legal issues to lay persons, both within the organization and to judges and juries. This book provides lawyers with invaluable and in-depth tactics and advice so that any pharmaceutical ANDA litigant wanting to increase market share, whether as an innovator or a generic, can plan early and be ready to alter plans as new events occur.

Topics include, but are not limited to:

  • Coordinating new drug application (NDA) and patent portfolio strategy
  • Preclinical R&D and patent considerations
  • Clinical trials and regulatory considerations
  • Trademark and nonproprietary name considerations
  • Acquiring and in-licensing pharmaceutical products
  • Prelitigation investigations and due diligence
  • Market entry business considerations for generic companies